Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models

Most anti-angiogenic therapies currently being evaluated in clinical trials target vascular endothelial growth factor (VEGF) pathway, however, the tumor vasculature can acquire resistance to VEGF-targeted therapy by shifting to other angiogenesis mechanisms. Therefore, other potential therapeutic ag...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Wu, Xiao Yu, Xu, Hao, Wu, Zhen Feng, Chen, Che, Liu, Jia Yun, Wu, Guan Nan, Yao, Xue Quan, Liu, Fu Kun, Li, Gang, Shen, Liang
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2015
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4792576/
https://ncbi.nlm.nih.gov/pubmed/26575424
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia